本研究对基于MRI的附件肿物评分系统研究进展进行综述。首先分别回顾ADNEX MR评分系统和O-RADS MRI评分系统的提出背景及其对超声下不确定的附件肿物的诊断性能和临床价值。其次,整理两大MRI评分系统的分类标准以及相关的MRI特征术语。再总结近年来两大评分系统的临床应用进展及局限性。最后,进一步讨论MRI评分系统未来的可能发展方向。本综述旨在为后续研究附件肿物的术前评估及准确分类方面提供一些可行的思路和建议。The present review examines the current landscape and emerging developments of MRI-derived scoring systems for characterizing adnexal masses. Firstly, the background of the ADNEX MR SCORING system and the O-RADS MRI scoring system were reviewed, and their diagnostic performance and clinical value for indeterminate adnexal masses under ultrasound were reviewed, respectively. Secondly, the classification criteria of the two MRI scoring systems and the related descriptive terms of MRI signs are organized. The clinical progress and limitations of the two scoring systems in recent years are then summarized, and finally, the possible future directions of MRI scoring systems are further explored and discussed. The aim of this study is to provide some feasible ideas and suggestions for subsequent studies on the preoperative evaluation and accurate classification of adnexal masses.
目的:探讨si RNA沉默检测点激酶1(Chk1)基因对人卵巢癌细胞HO8910增殖和周期调控的影响及其作用机制。方法:设计并合成3条Chk1 si RNA干扰片段,转染进入卵巢癌细胞HO8910,Western blot检测转染前后HO8910细胞中Chk1蛋白的表达情况,筛选出有效片段。将Chk1 si RNA有效片段转染进入HO8910细胞,采用MTT法和流式细胞仪分析Chk1si RNA对HO8910细胞增殖和周期的影响;Western blot方法分别检测细胞周期相关基因Cyclin A、CDK4、Cdc25A蛋白表达。结果:3个si RNA中,1条是有效si RNA。该有效Chk1 si RNA片段转染后,HO8910细胞中Chk1蛋白水平下降约53.6%,明显低于未转染组和脂质体转染组(P=0.000)。转染48 h后,Chk1 si RNA转染组HO8910细胞增殖活性下降,抑制率为(52.1±5.1)%,明显高于脂质体转染组的(7.6±3.8)%(P=0.000)。流式细胞仪检测显示Chk1 si RNA转染组HO8910细胞G2/M期比例为(5.03±2.62)%,明显低于未转染组(19.35±2.19)%和脂质体转染组(19.76±2.67)%(P=0.000)。Western blot结果显示转染Chk1 si RNA后,细胞内与细胞周期相关的Cyclin A、CDK4、Cdc25A蛋白水平表达明显增强,与未转染组和脂质体组比较,差异有统计学意义(P=0.000)。结论:si RNA沉默Chk1基因后,可明显抑制卵巢癌细胞HO8910细胞的增殖,其抑制增殖作用与减弱G2/M期阻滞有关。
